| 词条 | Kyowa Hakko Kirin |
| 释义 |
| name = Kyowa Hakko Kirin Co., Ltd. | logo = Kyowa Hakko Kirin Logo.svg | logo_size = 200px | type = Public (K.K) | traded_as = {{TYO|4151}} {{FWB|KY4}} Nikkei 225 Component | foundation = July 1, 1949 | image = 大手町フィナンシャルシティグランキューブ.jpg | location = Ohtemachi Building, 1-6-1, Ōtemachi, Chiyoda-ku, Tokyo 100-8185, Japan | key_people = Nobuo Hanai, (CEO and President) | num_employees = 7,532 (consolidated) (as of December 31, 2017) | products = {{unbulleted list|Biochemicals|Biosimilars|Diagnostics|Pharmaceuticals}} | homepage = {{Official website|http://www.kyowa-kirin.com/index.html}} | industry = {{unbulleted list|Pharmaceuticals|Biotechnology}} | footnotes = [1][2][3] | subsid = 47 (33 in Japan and 14 overseas countries) | parent = Kirin Holdings Company, Limited | revenue = $ 3.548 billion USD (FY 2013) | net_income = $ 31.32 million USD (FY 2013) }}{{nihongo|Kyowa Hakko Kirin Co., Ltd.|協和発酵キリン株式会社|Kyōwa Hakkō Kirin Kabushiki Kaisha}} is a Japanese pharmaceutical and biotechnology company under the Kirin Holdings, and is among the 40 largest in the world by revenue. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index.[4][5] HistoryOn July 1, 1949 the forerunner of the present company, Kyowa Hakko Kogyo Co., Ltd. is established. Following the merger with Kirin Pharma Co., Ltd., on October 1, 2008 the company changed its name to its present. On July 11, 2014, the KHK subsidiary, ProStrakan Group (based in Scotland), acquired Archimedes Pharma from the Novo Nordisk Foundation for $394 million [6] Business segments and products
The company developed a method to make afucosylated monoclonal antibodies using a CHO cell line in which FUT8 has been knocked out; the company calls this its "Potelligent" platform. The company gained marketing approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform.[7]
References1. ^{{cite web |url=http://www.kyowa-kirin.com/about_us/overview/index.html |title=Kyowa Hakko Kirin Company Overview |publisher=Kyowa Hakko Kirin |accessdate=March 14, 2014}} 2. ^{{cite web |url=http://www.kyowa-kirin.com/about_us/overview/pdf/corporate_profile_2013.4.pdf |title=Kyowa Hakko Kirin Corporate Profile |publisher=Kyowa Hakko Kirin |accessdate=March 14, 2014}} 3. ^{{cite web |url=http://asia.cdn.euroland.com/arinhtml/JP-KY4/2012/AR_ENG_2012/index.htm |title=Kyowa Hakko Kirin Annual Report 2012 |publisher=Kyowa Hakko Kirin |accessdate=March 14, 2014}} 4. ^{{cite web|url=http://indexes.nikkei.co.jp/en/nkave/index/component?idx=nk225#09 |title=Components:Nikkei Stock Average |publisher=Nikkei Inc. |accessdate=January 20, 2015}} 5. ^{{cite web|url=http://www.currentpartnering.com/insight/top-50-pharma/ |title=Top 50 Pharma Companies by 2012 Revenue |publisher=Wildwood Ventures Ltd. |accessdate=March 14, 2014}} 6. ^{{cite news |url = http://www.genengnews.com/gen-news-highlights/khk-s-prostrakan-acquires-archimedes-pharma-for-394m/81250094/|title = ProStrakan Acquires Archimedes Pharma for $394M|work = Genetic Engineering & Biotechnology News|publisher = Mary Ann Liebert, Inc.|date = July 11, 2014|accessdate = January 20, 2015}} 7. ^{{cite journal|last1=Yu|first1=X|last2=Marshall|first2=MJE|last3=Cragg|first3=MS|last4=Crispin|first4=M|title=Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.|journal=BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|date=June 2017|volume=31|issue=3|pages=151–166|doi=10.1007/s40259-017-0223-8|pmid=28466278}} 8. ^{{cite web|url=http://v4.eir-parts.net/v4Contents/View.aspx?template=ir_material_for_fiscal_ym&sid=7426&code=4151 |title=FY 2013 Consolidated Financial Summary |publisher=Kyowa Hakko Kirin |accessdate=March 14, 2014}} External links{{Portal|Japan|Medicine|Tokyo|Companies}}
7 : Biopharmaceutical companies|Biotechnology companies of Japan|Pharmaceutical companies based in Tokyo|Companies listed on the Tokyo Stock Exchange|Pharmaceutical companies established in 1949|1949 establishments in Japan|Japanese brands |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。